A dramatic shift in federal oversight permitting certain unapproved peptides has rattled pharmaceutical giants while igniting a boom for alternative wellness markets.

Mounting internal leadership friction and policy disputes within the American Psychological Association are prompting scrutiny across the healthcare and behavioral health landscape.